Despite its significance, BCL2A1 has a brief half‐life, largely due to ongoing processing by the ubiquitin–proteasome system, which serves as a crucial tumor‐suppressor mechanism governing BCL2A1 activity. This evidence concerns the gene BCL2A1 and neoplasm.